Business
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care Confere
About this update from Elicio Therapeutics, Inc.
[{"type":"image","alt":"Elicio Therapeutics Inc.","displaySize":"","headline":null,"caption":"Elicio Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dHRdNHTDYzkn3cTM5JZhnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995","width":300,"height":108}},"lazy":false},{"type":"text","content":"BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA.","length":459,"tagName":"p"},{"type":"text","content":"TD Cowen 46th Annual Health Care ConferenceFormat: Company presentationDate: Wednesday, March 4, 2026Time: 1:10 PM ET","length":120,"tagName":"p"},{"type":"text","content":"The live webcast and replay of the presentation will be available HERE and on Elicio’s Events page for 90 days following the event.","length":131,"tagName":"p"},{"type":"text","content":"If you are interested in arranging a 1×1 meeting with management at the conference, please contact your TD Cowen representative.","length":128,"tagName":"p"},{"type":"text","content":"About Elicio Therapeutics ","length":25,"tagName":"p"},{"type":"text","content":"Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherap...